{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T19:51:25Z","timestamp":1775159485737,"version":"3.50.1"},"reference-count":60,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Adisco Brescia"},{"name":"Department of Clinical and Experimental Sciences of University of Brescia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Exosomes are extracellular vesicles playing a pivotal role in the intercellular communication. They shuttle different cargoes, including nucleic acids from their cell of origin. For this reason, they have been studied as carriers of tumor markers in different liquid biopsy approaches, in particular for solid tumors. Few data are available concerning exosomes as markers of myeloid neoplasia. To better understand their real potential and the best approach to investigate leukemic exosomes, we present the results of a pilot feasibility study evaluating the application of next-generation sequencing analysis of dsDNA derived from exosomes isolated in 14 adult patients affected by acute myeloid leukemias. In particular, leukemia-derived exosome fractions have been analyzed. The concentration of dsDNA co-extracted with exosomes and the number and types of mutations detected were considered and compared with ones identified in the Bone Marrow (BM) and Peripheral Blood (PB) cells. Exosomal DNA concentration, both considering the cargo and the DNA surrounding the lipid membrane resulted in a linear correlation with leukemic burden. Moreover, exosomal DNA mutation status presented 86.5% of homology with BM and 75% with PB. The results of this pilot study confirmed the feasibility of a leukemia-derived exosome enrichment approach followed by exosomal dsDNA NGS analysis for AML biomarker detection. These data point to the use of liquid biopsy in myeloid neoplasia for the detection of active leukemic cells resident in the BM via a painless procedure.<\/jats:p>","DOI":"10.3390\/cancers14184504","type":"journal-article","created":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T22:12:43Z","timestamp":1663539163000},"page":"4504","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-2624","authenticated-orcid":false,"given":"Simona","family":"Bernardi","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"},{"name":"Centro di Ricerca Emato-Oncologica AIL (CREA), ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirko","family":"Farina","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katia","family":"Bosio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"},{"name":"Centro di Ricerca Emato-Oncologica AIL (CREA), ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Di Lucanardo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"},{"name":"Centro di Ricerca Emato-Oncologica AIL (CREA), ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Leoni","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Re","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"},{"name":"Centro di Ricerca Emato-Oncologica AIL (CREA), ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-9697","authenticated-orcid":false,"given":"Nicola","family":"Polverelli","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Turra","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0406-6579","authenticated-orcid":false,"given":"Enrico","family":"Morello","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Accorsi Buttini","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Zollner","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1577-2823","authenticated-orcid":false,"given":"Cristian","family":"Bonvicini","sequence":"additional","affiliation":[{"name":"Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni Di Dio Fatebenefratelli, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Malagola","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Sciences, University of Brescia, Bone Marrow Transplant Unit, ASST Spedali Civili, 25123 Brescia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"C29","DOI":"10.1152\/ajpcell.00280.2019","article-title":"Extracellular vesicles as biomarkers and therapeutic targets for cancer","volume":"318","author":"Urabe","year":"2020","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bernardi, S., and Balbi, C. (2020). Extracellular Vesicles: From Biomarkers to Therapeutic Tools. Biology, 9.","DOI":"10.3390\/biology9090258"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","article-title":"Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines","volume":"7","author":"Witwer","year":"2018","journal-title":"J. Extracell. Vesicles"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Gargiulo, E., Paggetti, J., and Moussay, E. (2019). Hematological Malignancy-Derived Small Extracellular Vesicles and Tumor Microenvironment: The Art of Turning Foes into Friends. Cells, 8.","DOI":"10.3390\/cells8050511"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3389\/fonc.2019.00528","article-title":"The minimal residual disease in non-hodgkin\u2019s lymphomas: From the laboratory to the clinical practice","volume":"9","author":"Galimberti","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Bernardi, S., and Farina, M. (2021). Exosomes and Extracellular Vesicles in Myeloid Neoplasia: The Multiple and Complex Roles Played by These \u201cMagic Bullets\u201d. Biology, 10.","DOI":"10.3390\/biology10020105"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Estey","year":"2017","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000437202","article-title":"Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia?","volume":"135","author":"Farina","year":"2016","journal-title":"Acta Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ajh.24312","article-title":"Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?","volume":"91","author":"Bernasconi","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/cncr.31837","article-title":"Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery","volume":"125","author":"Simonetti","year":"2019","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2015-04-641100","article-title":"Genomic analysis of germ line and somatic variants in familial myelodysplasia\/acute myeloid leukemia","volume":"126","author":"Churpek","year":"2015","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s41375-018-0051-y","article-title":"Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: Are we there yet?","volume":"32","author":"Tawana","year":"2018","journal-title":"Leukemia"},{"key":"ref_14","first-page":"2795656","article-title":"ETV6: A Candidate Gene for Predisposition to \u201cBlend Pedigrees\u201d? A Case Report from the NEXT-Famly Clinical Trial","volume":"2020","author":"Bernardi","year":"2020","journal-title":"Case Rep. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/JCO.2011.37.1203","article-title":"Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes","volume":"30","author":"Goldin","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/hon.2806","article-title":"Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia","volume":"38","author":"Borlenghi","year":"2020","journal-title":"Hematol. Oncol."},{"key":"ref_18","first-page":"3914828","article-title":"Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?","volume":"2019","author":"Malagola","year":"2019","journal-title":"Case Rep. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"123079","DOI":"10.1155\/2014\/123079","article-title":"Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation","volume":"2014","author":"Malagola","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/cam4.593","article-title":"Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients","volume":"5","author":"Malagola","year":"2016","journal-title":"Cancer Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1001\/jamaoncol.2020.4599","article-title":"Minimal Residual Disease in Acute Myeloid Leukemia","volume":"6","author":"Jeyakumar","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/hematology.2019000059","article-title":"Single-agent and combination biologics in acute myeloid leukemia","volume":"2019","author":"DiNardo","year":"2019","journal-title":"Hematology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/hematology.2020000088","article-title":"How to approach shared decision making when determining consolidation, maintenance therapy, and transplantation in acute myeloid leukemia","volume":"2020","author":"Walker","year":"2020","journal-title":"Hematology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/ajh.24246","article-title":"Acute myeloid leukemia-Major progress over four decades and glimpses into the future","volume":"91","author":"Kantarjian","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00277-020-04109-z","article-title":"dsDNA from extracellular vesicles (EVs) in adult AML","volume":"100","author":"Bernardi","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): Results from the AML Study Group","volume":"134","author":"Agrawal","year":"2019","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"15745","DOI":"10.1038\/s41598-020-72834-6","article-title":"Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients","volume":"10","author":"Zocco","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41525-017-0034-3","article-title":"Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection","volume":"2","author":"Liu","year":"2017","journal-title":"NPJ Genomic Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/nprot.2015.105","article-title":"Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR","volume":"10","author":"Yang","year":"2015","journal-title":"Nat. Protoc."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Colosini, A., Bernardi, S., Foroni, C., Pasinetti, N., Guerini, A.E., Russo, D., Bresciani, R., Tomasi, C., Magrini, S.M., and Bardoscia, L. (2022). Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061321"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/aca.ACA_157_18","article-title":"Descriptive Statistics and Normality Tests for Statistical Data","volume":"22","author":"Mishra","year":"2019","journal-title":"Ann. Card. Anaesth."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00277-019-03866-w","article-title":"Evaluation of dsDNA from extracellular vesicles (EVs) in pediatric AML diagnostics","volume":"99","author":"Kontopoulou","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Taylor, C., Chacko, S., Davey, M., Lacroix, J., Macpherson, A., Finn, N., Wajnberg, G., Ghosh, A., Crapoulet, N., and Lewis, S.M. (2020). Peptide-affinity precipitation of extracellular vesicles and cell-free dna improves sequencing performance for the detection of pathogenic mutations in lung cancer patient plasma. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239083"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/annonc\/mdx542","article-title":"Surfaceome profiling enables isolation of cancerspecific exosomal cargo in liquid biopsies from pancreatic cancer patients","volume":"29","author":"Castillo","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1158\/1078-0432.CCR-17-2007","article-title":"Liquid biopsies using plasma exosomal nucleic acids and plasma cell-free DNA compared with clinical outcomes of patients with advanced cancers","volume":"24","author":"Huang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12935-021-01761-x","article-title":"Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy","volume":"21","author":"Kim","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3389\/fgene.2020.00237","article-title":"Combination of Four Serum Exosomal MiRNAs as Novel Diagnostic Biomarkers for Early-Stage Gastric Cancer","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e1593805","DOI":"10.1080\/2162402X.2019.1593805","article-title":"Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT","volume":"8","author":"Theodoraki","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1080\/10428194.2018.1563692","article-title":"Evaluation of exosomal miR-155, let-7g and let-7i levels as a potential noninvasive biomarker among refractory\/relapsed patients, responsive patients and patients receiving R-CHOP","volume":"60","author":"Zare","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_40","first-page":"e89631","article-title":"Plasma vesicle miRNAs for therapy response monitoring in Hodgkin lymphoma patients","volume":"1","author":"Zijlstra","year":"2016","journal-title":"JCI Insight"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1080\/10428194.2016.1243790","article-title":"Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia","volume":"58","author":"Simeon","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/14737159.2016.1174578","article-title":"Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: Are we ready?","volume":"16","author":"Boyiadzis","year":"2016","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"14707","DOI":"10.1038\/s41598-018-32900-6","article-title":"Urinary Exosomal and cell-free DNA Detects Somatic Mutation and Copy Number Alteration in Urothelial Carcinoma of Bladder","volume":"8","author":"Lee","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"100734","DOI":"10.1016\/j.blre.2020.100734","article-title":"Deciphering the messages carried by extracellular vesicles in hematological malignancies","volume":"46","author":"Longjohn","year":"2021","journal-title":"Blood Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bjh.16579","article-title":"Minimal Residual Disease Monitoring in Acute Myeloid Leukaemia: Are We Ready to Move from Bone Marrow to Peripheral Blood?","volume":"190","author":"Malagola","year":"2020","journal-title":"Br. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00018-017-2595-9","article-title":"Current knowledge on exosome biogenesis and release","volume":"75","author":"Hessvik","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"108489","DOI":"10.1016\/j.clim.2020.108489","article-title":"Circulating cells and exosomes in acute myelogenous leukemia and their role in disease progression and survival","volume":"217","author":"Miyamoto","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-017-1295-z","article-title":"Circulating DNA in rheumatoid arthritis: Pathological changes and association with clinically used serological markers","volume":"19","author":"Rykova","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3324\/haematol.2018.206177","article-title":"Liquid biopsy in lymphoma","volume":"104","author":"Rossi","year":"2019","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Galbiati, S., Damin, F., Brambilla, D., Ferraro, L., Soriani, N., Ferretti, A.M., Burgio, V., Ronzoni, M., Vago, R., and Sola, L. (2021). Small EVs-Associated DNA as Complementary Biomarker to Circulating Tumor DNA in Plasma of Metastatic Colorectal Cancer Patients. Pharmaceuticals, 14.","DOI":"10.3390\/ph14020128"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/annonc\/mdv604","article-title":"Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes","volume":"27","author":"Allenson","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/pros.22853","article-title":"Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: Apoptotic bodies, microvesicles, and exosomes","volume":"74","author":"Visakorpi","year":"2014","journal-title":"Prostate"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018016378","article-title":"Evaluating measurable residual disease in acute myeloid leukemia","volume":"2","author":"Ravandi","year":"2018","journal-title":"Blood Adv."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Foroni, C., Zarovni, N., Bianciardi, L., Bernardi, S., Triggiani, L., Zocco, D., Venturella, M., Chiesi, A., Valcamonico, F., and Berruti, A. (2020). When less is more: Specific capture and analysis of tumor exosomes in plasma increases the sensitivity of liquid biopsy for comprehensive detection of multiple androgen receptor phenotypes in advanced prostate cancer patients. Biomedicines, 8.","DOI":"10.3390\/biomedicines8050131"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00277-019-03608-y","article-title":"Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicle\u2013derived RNA","volume":"98","author":"Kunz","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_56","first-page":"2133","article-title":"Feasibility of tumor-derived exosome enrichment in the onco-hematology leukemic model of chronic myeloid leukemia","volume":"44","author":"Bernardi","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1159\/000505088","article-title":"Exosomes in Chronic Myeloid Leukemia: Are We Reading a New Reliable Message?","volume":"143","author":"Bernardi","year":"2020","journal-title":"Acta Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Skert, C., Perucca, S., Chiarini, M., Giustini, V., Sottini, A., Ghidini, C., Martellos, S., Cattina, F., Rambaldi, B., and Cancelli, V. (2017). Sequential monitoring of lymphocyte subsets and of T-and-B cell neogenesis indexes to identify time-varying immunologic profiles in relation to graft-versus-host disease and relapse after allogeneic stem cell transplantation. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175337"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: A consensus process by an EBMT\/ELN international working group","volume":"29","author":"Deeg","year":"2015","journal-title":"Leukemia"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5045\/br.2018.53.1.3","article-title":"The role of allogeneic hematopoietic stem cell transplantation in the four P medicine era","volume":"53","author":"Morello","year":"2018","journal-title":"Blood Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/18\/4504\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:33:15Z","timestamp":1760142795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/18\/4504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":60,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["cancers14184504"],"URL":"https:\/\/doi.org\/10.3390\/cancers14184504","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]}}}